Esperion Therapeutics Acquired by ArchiMed | Healthcare M&A Deal

ArchiMed has entered into a merger acquisition agreement to acquire Esperion Therapeutics, a pharmaceuticals business in the United States. Esperion Therapeutics develops and commercializes therapies focused on metabolic and cardiovascular conditions, supporting its role in healthcare M&A. ArchiMed acquisitions in pharmaceuticals aim to expand a private equity acquisition portfolio with clinical and commercial-stage assets. The deal is structured as a merger acquisition and remains announced, with deal size undisclosed.